VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma

Multiple Myeloma Clinical Trial

— VISION  

Official title:

A Multi-center,Open, Longitudinal, Observational Study to Evaluate the Treatment Effectiveness and Safety of the Bortezomib-melphalan-prednisolone Regimen in Treatment-naïve Patients With Multiple Myeloma, Ineligible for Hematopoietic Transplantation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04151615
• Other study ID #: BR-BTZ-OS-401
• Status: Completed
• Start date: November 15, 2018
• Est. completion date: January 11, 2023

Study information

• Verified date: June 2023
• Source: Boryung Pharmaceutical Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The 3-drug therapy of Bortezomib-Melphalan-Prednisolone (VMP) is a standard therapy that is commonly used currently in South Korea as a first-line treatment for treatment-naïve patients with multiple myeloma who are ineligible for hematopoietic transplantation. Despite the fact that VMP therapy is outstanding in terms of cost-effectiveness, treatment discontinuation rates due to adverse drug reactions is high. In addition, when considering that the percentage of elderly patients aged 70 years or above in the target patient group is 20% or above, there have been attempts to devise a plan that can decrease side effects while maintaining effectiveness. For example, there have been previous reported cases of overseas applications of modified VMP therapies with reduced doses, but they have applied various combinations in terms of the total cycles, administration intervals, doses, etc. This study was planned to evaluate the overall safety and efficacy of VMP therapy by following up on the actual VMP therapies applied in domestic clinics, patient characteristics, side effect occurrences, administration discontinuation rates, survival data, etc., as well as to collect exploratory data for a more effective study of modified VMP therapies.

This study was planned to evaluate the overall safety and efficacy of VMP therapy by following up on the actual VMP therapies applied in domestic clinics, patient characteristics, side effect occurrences, administration discontinuation rates, survival data, etc., as well as to collect exploratory data for a more effective study of modified VMP therapies.

Description:

The data produced when subjects visit the hospital for treatment are collected in case report forms. The follow-up time specified in the following refer to the data collection time. That is, a subject's visit schedule is freely determined by the investigator based on the medical condition of the subject regardless of the follow-up time specified in this protocol, but data that are determined necessary in relation to the study among the data produced during the study period may be collected in CRFs.

In regard to various tests for monitoring of treatment effects including laboratory tests, the corresponding tests are not performed separately for this clinical study, and only those items with existing test results are collected. The following data are collected in CRFs during the study period.

• Demographic information of subjects

• Information on multiple myeloma disease (diagnosis date, diagnosis criteria and related test results, disease stage [ISS and revised ISS], number of osseous lesions)

• Intercurrent diseases

• Height and body weight

• ECOG PS

• IMWG Frailty score

• Laboratory results

• Radiologic results

• Bone marrow examination results

• Supportive therapy administered for symptoms related to multiple myeloma (drug / surgery / radiotherapy)

• Detailed information of administered VMP therapy

• Maintenance therapy / VMP replacement therapy

• Clinical response

• Survival

• Adverse drug reactions related to VMP therapy

• Serious adverse events/adverse drug reactions

Recruitment information / eligibility

• Status: Completed
• Enrollment: 203
• Est. completion date: January 11, 2023
• Est. primary completion date: January 11, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• Patients who provide written consent on the informed consent form for use of personal information after listening to an explanation regarding the purpose, method, etc., of this clinical study

• Adult males and females aged 19 years or above

• Patients without previous experience of treatment for multiple myeloma who have been evaluated as ineligible for hematopoietic transplantation

• Patients scheduled to receive the 3-drug combination (VMP therapy) treatment

• Patients with expected survival period of 6 months or more

• Patients evaluated as having performance status score (ECOG PS) =2 (score of 0, 1, 2)

• Patients who have received the following tests within 6 months prior to enrollment

• Beta2-microglobulin

• Serum albumin

• Serum LDH

• Patients with confirmed del (17), t (4;14), t (14;16) by hybridization FISH test

Exclusion Criteria:

• Patients who have been newly diagnosed with other primary cancers within the last 5 years that can affect the treatment or prognosis of multiple myeloma

• Pregnant women and breast-feeding women

• Patients who are currently participating in other clinical studies (drug or medical device clinical studies) or planning to participate in other clinical studies during the study participation period

• Patients who are determined ineligible to participate in the study by other judgments of the investigator

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Locations

Country	Name	City	State
Korea, Republic of	Soonchunhyang University Bucheon hospital	Bucheon
Korea, Republic of	Inje university Haeundae Paik Hospital	Busan
Korea, Republic of	Kosin University Gospel hospital	Busan
Korea, Republic of	Pusan national University Hospital	Busan
Korea, Republic of	Chungbuk national university Hospital	Chungbuk
Korea, Republic of	Dankook University Hospital	Chungnam
Korea, Republic of	Keimyung University Hospital(Dongsan Medical Center)	Daegu
Korea, Republic of	Yeungnam University Medical Center	Daegu
Korea, Republic of	Chungnam National University Hospital	Daejeon
Korea, Republic of	National Cancer Center	Goyang
Korea, Republic of	Gyeongsang National University Changwon Hospital	Gyeongsang
Korea, Republic of	Chonnam National University Hwasun Hospital	Hwasun
Korea, Republic of	Gachon University Gil Medical Center	Incheon
Korea, Republic of	Chung-Ang University Hospital	Seoul
Korea, Republic of	Kangbuk Samsung Hospital	Seoul
Korea, Republic of	Korea University Anam Hospital	Seoul
Korea, Republic of	Samsung Medical Center	Seoul
Korea, Republic of	Seoul National University Hospital	Seoul
Korea, Republic of	Severance Hospital	Seoul
Korea, Republic of	Soonchunhyang University Hospital	Seoul
Korea, Republic of	The Catholic University of Korea, Seoul ST. Mary's Hospital	Seoul
Korea, Republic of	Ajou University Medical Center	Suwon
Korea, Republic of	Ulsan University hospital	Ulsan
Korea, Republic of	Wonju Severance Christian Hospital	Wonju

Sponsors (1)

Lead Sponsor	Collaborator
Boryung Pharmaceutical Co., Ltd

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PFS (progression-free survival)	the survival rate curve of PFS and the median, as well as the 95% confidence interval for this are presented. An event is 'confirmation of progressive disease (PD)' or 'death,' and others are processed as censored at the later time point between the final follow-up time point and the time point of final clinical response evaluation.	18 Month after VMP therapy administration
Secondary	ORR (Overall Response Rate)	The frequency and percentage of subjects who reach CR, VGPR, and PR even once after VMP therapy administration are calculated, and the 95% CI for the percentage is presented.	18 Month after VMP therapy administration
Secondary	CR (Complete Response)	The frequency and percentage of subjects who reach CR even once after VMP therapy administration are calculated, and the 95% CI for the percentage is presented	18 Month after VMP therapy administration
Secondary	Time to Response (TTR)	time to first response and time to best response; here, response must be higher than partial response (PR).	18 Month after VMP therapy administration
Secondary	Time to Progression (TTP)	'confirmation of progressive disease,' and others are processed as censored at the final follow-up time point or the time point of final clinical response evaluation.	18 Month after VMP therapy administration
Secondary	Time to Next Treatment (TTNT)	'administration of VMP replacement therapy (regardless of VMP therapy termination),' and others are processed as censored at the final follow-up	18 Month after VMP therapy administration
Secondary	OS (Overall Survival)	'death,' and others are processed as censored at the final time point with confirmed survival.	18 Month after VMP therapy administration
Secondary	Percentage of IMWG frailty scores at Cycle 5 and Cycle 9	The frequency and percentage of IMWG frailty scores (Fit: 0 points, Intermediate-fitness: 1 point, Frail: =2 points) per time point are presented. The mean, standard deviation, median, minimum value, and maximum value for the variance of IMWG frailty scores at VMP therapy Cycle 5 and Cycle 9 compared to the baseline are summarized with descriptive statistics	18 Month after VMP therapy administration
Secondary	Prognosis prediction factors	Prognosis variables: PFS/TTR/TTP/OS; Potential prediction factors: Age / ISS stage / revised ISS stage / number of osseous lesions / IMWG frailty score at baseline (0 points, 1 point, =2 points) / VMP administration pattern	18 Month after VMP therapy administration